 meeting){kind=link}
CareDx and Dovetail Genomics have joined forces to take a significant step forward in the way organ and stem cell transplants are matched. The collaboration aims to make HLA genotyping more precise, which could help improve donor-recipient compatibility, ultimately increasing the chances of long-term success for transplant patients.
CareDx, will incorporate Dovetail Genomics’ Hi-C LinkPrep™ technology into its AlloSeq™ Tx 17 HLA typing solution. This combination will give labs access to high-resolution genotyping and haplotyping—without the need for family genotyping studies—allowing for a more detailed look at potential matches between donors and recipients.
John W. Hanna, CareDx’s President and CEO, noted that this partnership reflects the company’s ongoing efforts to push innovation in transplant medicine. “We’re excited to offer HLA labs early access to new tools that could really help with matching donors and recipients more effectively,” Hanna said.
Dovetail’s technology allows for a better understanding of genetic variation across the HLA region, which plays a crucial role in transplant compatibility. “We see this as a new and important tool for the transplant community,” said Matt Easterday, CEO of Dovetail Genomics.
Both companies plan to present their findings at the upcoming American Society for Histocompatibility and Immunogenetics (ASHI) meeting, where attendees can learn more about how this partnership could reshape the future of transplant matching. Labs interested in trying the new technology will be able to participate in an Early Access Program.